Article Sidebar

PDF
Date Published: 22/08/2023
Abstract Views: 136
Views PDF: 132
DOI: https://doi.org/10.56535/jmpm.v48i6.359
Issue
Vol. 48 No. 6 (2023): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 6 - 2023
Section
Articles
How to Cite
Vibounmy, K., Nguyen, T. K., Ha, T. D., & Le, V. T. (2023). REMARK ON THE TACROLIMUS TROUGH CONCENTRATION AT THE 12th MONTH IN KIDNEY TRANSPLANT PATIENTS AT MILITARY HOSPITAL 103. Journal of Military Pharmaco-medicine, 48(6), 70-77. https://doi.org/10.56535/jmpm.v48i6.359

REMARK ON THE TACROLIMUS TROUGH CONCENTRATION AT THE 12th MONTH IN KIDNEY TRANSPLANT PATIENTS AT MILITARY HOSPITAL 103

Keovithoun Viboun , Nguyen Trung Kien1,2, Ha Thiem Dong, Le Viet Thang1,2
1 Vietnam Medical Military University
2 Military Hospital 103

Main Article Content

Abstract

Objectives: To investigate the Tacrolimus trough concentration at the 12th month in kidney transplant patients at Military Hospital 103. Methods: An observational, prospective study was conducted on 87 kidney transplant patients from living donors, followed up for 12 months post-transplant at Nephrology and Hemodialysis Department, Military Hospital 103, from February 2022 to December 2022. Results: 55.2% of patients used a TAC dose from 0.1 - 0.2 mg/kg/day, and no patient used more than 0.2 mg/kg/day. The proportion of patients with TAC trough concentration (C0) reaching the recommended level was 62.1%; those with C0 below and above the recommended level accounted for 20.7% and 17.2%, respectively. The median value of TAC C0 was 6.5 ng/mL. There was no difference in mean glomerular filtration rate between the three groups with TAC C0 levels lower, within and higher than recommendations. Conclusion: Most kidney transplant patients at 12 months post-transplant used a TAC dose from 0.1 - 0.2 mg/kg/day. The rate of reaching the recommended TAC C0 concentration was 62.1%.

Article Details

Keywords

Tacrolimus, C0, Kidney transplants

References

1. Hà Hoàng Kiệm. Suy thận mạn tính. Bệnh học nội khoa. Nhà xuất bản Quân đội Nhân dân, Hà Nội. 2008: 316-320.
2. Augustine J. Kidney transplant: New opportunities and challenges. Cleve Clin J Med. 2018; 85(2):138-144.
3. Hill N.R., Fatoba S.T., Oke J.L., et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7): e0158765.
4. Nevins T.E., Nickerson P.W., and Dew M.A. Understanding Medication Nonadherence after Kidney Transplant. J Am Soc Nephrol. 2017; 28(8):2290-2301.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3:S1-155.
6. Bùi Văn Mạnh. Nghiên cứu lâm sàng, cận lâm sàng và một số chỉ số
miễn dịch ở bệnh nhân sau ghép thận. Luận án tiến sĩ y học. Học viện Quân y, Hà Nội. 2009.
7. Banas B., Krämer B.K., Krüger B., et al. Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus. Transplant Proc. 2020; 52(1):102-110.
8. Nguyen T. Van Anh, Le Viet Thang, and Bui Van Manh. Tacrolimus Therapeutic Drug Monitoring in Vietnamese Renal Transplant Recipients. Pharmacogn J. 2020; 12(5):984-992.
9. Nguyễn Mạnh Tưởng. Nghiên cứu nồng độ glucose máu lúc đói và đặc điểm đái tháo đường ở bệnh nhân ghép thận. Luận văn chuyên khoa cấp II. Học viện Quân y, Hà Nội. 2018.
10. Gaynor J.J., Ciancio G., Guerra G., et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016 ; 29(2):216-226.